Position in NMRA
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$12,785
+$2,294 QoQ
Shares Held
7,521
+39.8% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#96
of 111 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NMRA Over Time
Shares Held
Position Value (USD)
Derivatives in NMRA
reported options exposure · as of Jun 30, 2026CallValue
$17,000
CallShares
10,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. NMRA ranks #116 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in NMRA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,785 | 7,521 | Shares | Sole | 2026-08-03 | |
| 2026-06-30 | $17,000 | 10,000 | Call | Sole | 2026-08-03 | |
| 2026-03-31 | $10,491 | 5,380 | Shares | Sole | 2026-05-13 | |
| 2026-03-31 | $16,575 | 8,500 | Call | Sole | 2026-05-13 | |
| 2025-12-31 | $38,127 | 21,300 | Call | Sole | 2026-02-13 | |
| 2025-12-31 | $62 | 35 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||